ArticleChinese medicine2026
Why the same herb is not the same medicine: plant epigenetic and metabolic plasticity as a missing variable in Chinese medicine.
Article in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Traditional Chinese medicine (TCM) standardization is largely based on chemical equivalence, yet achieving reproducible therapeutic efficacy remains challenging. This limitation reflects an implicit assumption that medicinal plants are chemically static materials, overlooking their nature as dynamically regulated biological systems. This commentary emphasizes plant epigenetic and metabolic plasticity as a missing dimension in current quality assessment strategies. Environmental and developmental factors can establish stable regulatory states through epigenetic mechanisms, including DNA methylation and histone modification, thereby shaping metabolic organization beyond immediate growth conditions. Because therapeutic efficacy emerges from coordinated metabolic networks, evaluation based solely on static chemical composition is inherently limited. I propose an epigenetically informed materia medica framework for next-generation quality assessment. By integrating dynamic metabolic signatures, such as metabolite relationships and pathway coordination, with epigenetic indicators of regulatory history, this approach redefines consistency as predictable functional performance rather than chemical uniformity. This perspective provides a biologically realistic foundation for improving reproducibility while aligning standardization with the systemic principles of herbal therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.